us earns acadia pharmaceuticals 110909
On the homepage
Vikings
Out There
Artcetera
Table Talk
Acadia Pharmaceuticals' 3rd-quarter loss narrows on revenue from drug development partners
Print this story
E-mail this story
Save to del.icio.us
Share on Facebook
Share on Digg
Minnesota business by the numbers
See Minnesota's top earning companies, CEOs and non-profits
More from Business
SAN DIEGO - Acadia Pharmaceuticals Inc. said Monday its third-quarter loss narrowed on lower costs and a boost in revenue from its drug development partners.
The development-stage biopharmaceutical company lost $8.7 million, or 23 cents per share, compared with a loss of $15.6 million, or 42 cents per share, during the same period a year prior. Revenue surged to $2.4 million from $282,000, mainly on the company's collaboration with Biovail.
Analysts expected a loss of 24 cents per share.
The company is working with Biovail on pimavanserin as a potential Parkinson's disease treatment and schizophrenia therapy. They've been partners since May.
Recent Business stories
Tech Data 3Q profit more than doubles as falling costs offset weaker revenue - November 9, 2009
Tech Data 3Q profit more than doubles as falling costs offset weaker revenue - Tech Data Corp. on Monday said its third-quarter net income more than doubled as lower interest expenses and a smaller foreign-exchange loss more than offset a decline in revenue. More
Blog: Patent Pending
Lights out at U energy conference. Irony police notified.
Just as Lawrence Kazmerski, a top official at the National Renewable Energy Laboratory, was about to give the keynote address at the University of Minnesota's annual E3 conference at the RiverCentre in St. Paul, the lights went out, bathing the audience in darkness and a deep sense of irony.
Comment on this story | Be the first to comment | Hide reader comments